Surface Oncology, Inc.
SURFDelisted Sep 8, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001718108
Surface Oncology, Inc. was delisted on Sep 8, 2023; its insiders filed their last Form 4 on Sep 8, 2023; 62 institutions reported holding it in 13F filings for Q2 2023, worth $16.9M in total; ARK Invest was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Surface Oncology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Surface Oncology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Oneill Alison | Chief Medical Officer | 0 | Sep 8, 2023 | 0 |
| Palombella Vito J. | Chief Scientific Officer | 0 | Sep 8, 2023 | 0 |
| Goater Jeff | Director | 0 | Sep 8, 2023 | 0 |
| Sigal Charles Elliott | Director | 0Indirect | Sep 8, 2023 | 0 |
| Grayzel David S. | Director | 0Indirect | Sep 8, 2023 | 0 |
| Ross Robert W. | Chief Executive Officer | 0 | Sep 8, 2023 | 0 |
| Fees Jessica | Chief Financial Officer | 0 | Sep 8, 2023 | 0 |
| Rath Henry C. | Chief Business Officer | 0 | Sep 8, 2023 | 0 |
| Adams Chandra | Deputy GC | 0 | Sep 8, 2023 | 0 |
| Brunn Carsten | Director | – | Jun 30, 2022 | 0 |
| Stelzer Laurie | Director | – | Jun 10, 2022 | 0 |
| Shanafelt Armen | Director, 10% Owner | – | Jun 10, 2022 | 0 |
| Hickey Benjamin | Director | – | Jun 10, 2022 | 0 |
| Ibrahim Ramy | Director | – | Jun 10, 2022 | 0 |
| Torres Denice | Director | – | Jun 10, 2022 | 0 |
| Boni Theresa | General Counsel & Secretary | – | Apr 1, 2022 | 0 |
| Nogelo Liisa I | Chief Legal Officer | 53,675 | Jan 14, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2023 (view filing) | Aug 1 | 10 daysLate | Oneill AlisonChief Medical Officer | SSale | −7.04K | $0.94 | −$6.62K | −11.1%56.7K after | |
| Aug 11, 2023 (view filing) | Aug 1 | 10 daysLate | Adams ChandraDeputy GC | SSale | −3.90K | $0.94 | −$3.67K | −11.2%30.9K after | |
| Aug 11, 2023 (view filing) | Aug 1 | 10 daysLate | Fees JessicaChief Financial Officer | SSale | −9.43K | $0.94 | −$8.87K | −8.5%101.9K after | |
| Aug 11, 2023 (view filing) | Aug 1 | 10 daysLate | Ross Robert W.Chief Executive Officer | SSale | −16.7K | $0.94 | −$15.7K | −16.7%83.2K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Rath Henry C.Chief Business Officer | SSale | −5.68K | $1.72 | −$9.76K | −14.9%32.3K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Oneill AlisonChief Medical Officer | SSale | −4.46K | $1.72 | −$7.68K | −6.5%63.7K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Ross Robert W.Chief Executive Officer | SSale | −10.6K | $1.72 | −$18.2K | −9.6%99.9K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Fees JessicaChief Financial Officer | SSale | −5.98K | $1.72 | −$10.3K | −5.1%111.3K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Palombella Vito J.Chief Scientific Officer | SSale | −4.46K | $1.72 | −$7.68K | −4.9%87.2K after | |
| Jan 14, 2022 (view filing) | Jul 21, 2021 | 177 daysLate | Goater JeffDirector | SSale | −127.8K | $6.10 | −$779.4K | −49.7%129.2K after | |
| Jan 14, 2022 (view filing) | Jul 21, 2021 | 177 daysLate | Fees JessicaChief Financial Officer | SSale | −19.9K | $6.10 | −$121.1K | −20.0%79.3K after | |
| Jan 14, 2022 (view filing) | Jul 21, 2021 | 177 daysLate | Palombella Vito J.Chief Scientific Officer | SSale | −26.3K | $6.10 | −$160.6K | −32.9%53.7K after | |
| Jan 14, 2022 (view filing) | Jul 21, 2021 | 177 daysLate | Ross Robert W.Chief Executive Officer | SSale | −33.5K | $6.10 | −$204.3K | −38.1%54.5K after | |
| Jan 14, 2022 (view filing) | Jul 21, 2021 | 177 daysLate | Nogelo Liisa IChief Legal Officer | SSale | −26.3K | $6.10 | −$160.6K | −32.9%53.7K after | |
| Jan 14, 2022 (view filing) | Jul 21, 2021 | 177 daysLate | Oneill AlisonChief Medical Officer | SSale | −14.8K | $6.10 | −$90.3K | −32.9%30.2K after |